Originally published by our sister publication Specialty Pharmacy Continuum
By SPC Staff
The FDA approved adalimumab-ryvk (Simlandi, Alvotech and Teva Pharmaceuticals) injection, the first interchangeable high-concentration, citrate-free biosimilar to adalimumab (Humira, AbbVie).
According to the FDA, an interchangeable biosimilar may be substituted at the pharmacy for the reference product without the intervention of the prescribing healthcare provider, much like how generic drugs are routinely